The abnormal accumulation of antibody-producing immune cells in the lungs may contribute to IPF progression, a new study ...

The study in the European Respiratory Journal used advanced spatial mapping techniques to compare healthy lung tissues and ...

A recent study published by Rutgers Health experts in the European Respiratory Journal identified interconnected webs of ...

Idiopathic pulmonary fibrosis is a progressive and life-threatening lung disease but there are ASX companies bringing hope to ...

Eric Cannon, PharmD, FAMCP, discusses how precision medicine advancements and biomarker development can enable targeted ...

The 2024 Professor Franz Brandstetter Prize, awarded by the Association of Supporters of the Leibniz Institute of Polymer Research Dresden (abbrev. IPF in German), has been presented to My Duyen Pham ...

Interim results demonstrate GRI-0621 to be safe and well-tolerated in the first 12 patients evaluated Currently available treatments for IPF are limited to only two approved drugs that come with ...

Rein Therapeutics, Inc. (NASDAQ: RNTX), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to ...

GRI Bio Inc.’s oral version of tazarotene is showing phase IIa promise in idiopathic pulmonary fibrosis (IPF). The peek at interim safety with the compound, a RAR-βɣ dual agonist designed to inhibit ...